A
Athenex
Athenex is focused on the development and commercialization of therapies for cancer and immunomodulatory diseases
At a glance
- Status
- Listed
- Founded
- 2003
- Headquarters
- Buffalo, United States
- Listing
- IPO 2017
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- EAErie County Industrial Development Agency
Series B and later1 investor entered at this stage
- UBUniversity of Buffalo
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Patents
37 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Athenex was the backer or acquirer, 2014–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
3 deals across Athenex's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Athenex's portfolio, mapped.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Athenex on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Athenex on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.